Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Surgery|May 17, 2020
Disparities in utilization of services for racial and ethnic minorities with hepatocellular carcinoma associated with hepatitis CAaron Kangas-Dick, Victor Gall, Patrick Hilden, et al.
American Journal of Surgery|July 1, 2015
Pancreaticoduodenectomy hospital resource utilization in octogenariansRussell C Langan, Chun-Chih Huang, Weisheng Renee Mao, et al.
Journal of Pancreatic Cancer|August 9, 2020
Subcategorizing T1 Staging in Pancreatic Adenocarcinoma Predicts Survival in Patients Undergoing Resection: An Analysis of the National Cancer DatabaseMihir M Shah, Rachel E NeMoyer, Stephanie H Greco, et al.
Journal of Cancer|June 7, 2012
A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as BiomarkersRussell C Langan, John E Mullinax, Satyajit Ray, et al.
Surgery Open Science|January 25, 2021
Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer DatabaseStephanie H Greco, David A August, Mihir M Shah, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing ResearchRitesh Kumar, Jongmyung Kim, Matthew P Deek, et al.
Surgery|April 1, 2014
Laparoscopic-assisted versus open pancreaticoduodenectomy: early favorable physical quality-of-life measuresRussell C Langan, Jay A Graham, Anne B Chin, et al.
Cancer Medicine|January 8, 2024
Recurrence-free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trialsEmma Vail, Ankur P Choubey, H Richard Alexander, et al.
Surgery|February 29, 2024
Racial disparities in rates of invasiveness of resected intraductal papillary mucinous neoplasms in the United StatesWilliam E Allen, Joshua D Greendyk, H Richard Alexander, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapyShane S Neibart, Swati Mamidanna, Anupama Chundury, et al.
Pageof 6